Specific Biologics has closed an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners to advance gene-editing therapy for ALS.
PRIVATENov 02, 2026
Amount Raised
$35 Million
Round Type
Series A
TorontoInformation TechnologyBiotechnologyHealth CareScience And EngineeringLending And Investments
Investors
Seido CapitalDeepWork CapitalBusiness Development Bank Of CanadaGenesys CapitaladMare BioInnovationsLumira VenturesHatteras Venture Partners
Description
Specific Biologics, a biotechnology company, has secured US$35 million in Series A financing. The funding will be used to develop their lead therapeutic candidate through initial clinical trials for ALS. The round saw participation from various foundational and new investors. This financing aims to create new treatment options for patients suffering from genetic diseases.
Who to call at Specific Biologics, and when
A new round usually means Specific Biologics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Specific Biologics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Specific Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Specific Biologics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Specific Biologics
Location
Toronto, Ontario, Canada
About
Specific Biologics Inc. ("Specific") is a venture-backed early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through efficient and precise gene editing. Our differentiated two-site Dualase® platform gene editors cut DNA in a way that optimally exploits the cell's naturally occurring DNA repair pathways. This enables two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes to target new therapeutic areas for gene editing. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of Dualase®-based therapeutics in areas of high unmet medical need. To learn more, visit www.specificbiologics.com.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Specific Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TorontoInformation TechnologyBiotechnologyHealth CareScience And EngineeringLending And Investments